培美曲塞二线治疗非小细胞肺癌的临床观察  

Clinical observation of pemetrexed in second-line treatment of non-small cell lung cancer

作　　者：何梅[1] 吴玉枝[1] 刘维萍[1] 赵秀娟[1] 张爱珍[1] 

机构地区：[1]山西省人民医院呼吸科,太原030012

出　　处：《中国临床新医学》2013年第9期876-877,共2页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：目的观察培美曲塞二线单药治疗非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法选择经病理及细胞学诊断为NSCLC患者25例,均有可测量和评估的病灶。给予培美曲塞500 mg/m2加入0.9%氯化钠100 ml中静滴,21 d为1周期,连用2~4周期。结果总有效率为8%,临床获益率为72%。主要毒副反应是Ⅰ~Ⅱ度骨髓抑制。结论培美曲塞治疗复发、转移的NSCLC有较好的临床获益率,不良反应小,值得临床推广应用。Objective To observe the clinical effect and toxicity of pemetrexed monotherapy in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods Twenty-five patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study.The patients received pemetrexed 500 mg / m2on d1,intravenously every 21 days as one cycle and the effects were evaluated after 2 ~ 4 cycles.Results The total response rate was 8%.The clinical benefit rate was 72%.The main toxicity was Grade Ⅰ ~ Ⅱ hematological toxicity.Conclusion Pemetrexed is an effective therapy for the patients with advanced NSCLC.Its efficacy is better,the toxicities can be tolerated and is worth clinical promotion.

关 键 词：非小细胞肺癌 培美曲塞 疗效 毒副反应 

分 类 号：R743[医药卫生—神经病学与精神病学]